Clinical Trial

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Recruiting Phase 4

Summary

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.

Protocol Amendment History 3 changes

critical Recruitment opened 2026-06-13

notable Primary completion pushed: 2027-10-06 -> 2027-12-03 2026-06-13

minor Completion pushed: 2027-12-30 -> 2028-02-25 2026-06-13

Trial Details

NCT Number	NCT07257484
Lead Sponsor	Weill Medical College of Cornell University Collaborators: National Center for Advancing Translational Sciences (NCATS)
Conditions	Obesity (Disorder), Breast Cancer
Enrollment	30 participants
Start Date	2026-06-08
Primary Completion	2027-12-03 (estimated)
Study Completion	2028-02-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-22